Glenmark Pharmaceuticals Limited CC-Sep23.pdf · 2023-11-15
Two questions. One is that the Ichnos spend in the first half has been higher than full year run rate guided of $60 milli on. So, how should one look at that in the second half? And secondly, this 200-basis points margin expansion next year is only from R&D or you're building in the RYALTRIS and the operating leverage in that?
How much of the Zetia payment has already been made and how much is pending? And also, in the balance sheet, there's one item called other current asset which has gone up in six months by almost 400 crores. So, what is that for?